DVA

Business profile & competitive position

DaVita Inc. (DVA) sits in the Healthcare sector, specifically the Medical - Care Facilities industry. Per its most recent 10-K, the company is one of the largest U.S. providers of kidney dialysis and related laboratory services, primarily serving patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the U.S. dialysis network consisted of 2,657 outpatient centers treating approximately 200,500 patients. Beyond dialysis, DaVita runs integrated kidney-care operations, ancillary services, hospital inpatient dialysis, home-based dialysis, transplant support, and an international business spanning 585 outpatient centers across 14 countries serving roughly 94,500 patients.

Scale is the defining feature. The company reports that U.S. dialysis revenues represented approximately 86% of consolidated revenues, and nearly all non-hospital dialysis profits came from commercial payors. That concentration means the moat is less about product differentiation and more about network density, payor contracts, and quality metrics. DaVita has led CMS’s Quality Incentive Program for the 11 most recently reported years and CMS’s Five-Star Quality Rating System for the 10 most recently reported years, which supports its credibility in a heavily regulated reimbursement environment.

Financially, the margin and return figures are worth reading together. Net margin is 6.0%, which shows that dialysis operations do produce bottom-line profit relative to sales. However, return on equity is -123.6%. A positive net margin paired with deeply negative ROE usually signals that reported shareholder equity is compressed, often through leverage, significant distributions, or share repurchases; it is not, by itself, evidence of operational losses. For competitive-position analysis, the implication is that DaVita generates cashflow from dialysis but runs a capital structure where book equity is thin or negative.

Financial posture

DaVita currently trades at $175.78, carries an $11.3B market capitalization, and trades at a P/E of 15.1. The beta is 0.87, meaning the stock has historically moved less sharply than the broad market, consistent with a defensive healthcare-services profile. The snapshot shows a 6.0% net margin and the already noted -123.6% ROE, so valuation ratios should not be read in isolation.

A P/E around 15.1 looks modest on the surface, but when ROE is -123.6% the earnings are being generated on a balance sheet with little or negative book equity. That structure can make traditional return-based valuation frameworks less informative and places greater analytical weight on free cash generation, debt service capacity, and the sustainability of commercial-payor pricing. From a price-action perspective, the stock is currently below its 50-day EMA of $197.54 and the RSI is 31.6, near the lower end of the range that technicians often watch for short-term oversold readings.

Strategic priorities & outlook

The company’s most recent 10-K outlines three operational priorities that frame its near-term strategy. First, DaVita wants to “reimagine high-quality kidney care” so that it is more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated-care capabilities that coordinate treatment along the renal care continuum, from chronic kidney disease to end-stage kidney disease and eventually kidney transplant. Third, it is supporting the Comprehensive Kidney Care Contracting (CKCC) model goals of delaying disease progression, promoting home dialysis when clinically appropriate, and incentivizing transplants.

These priorities point to a business trying to move beyond a volume-based dialysis model toward value-based, longitudinal kidney care. International expansion remains a smaller but meaningful footprint, with 94,500 patients across 14 countries providing optionality outside the U.S. reimbursement environment.

Macro & geopolitical exposure

Because DaVita operates in Medical - Care Facilities, its exposures map closely to the U.S. healthcare-policy and reimbursement cycle. Dialysis reimbursement is heavily influenced by Medicare, Medicaid, and CMS rate-setting, so changes to fee schedules or bundled-payment rules can flow directly into revenue. The company also participates in value-based care programs such as CKCC, which means performance on quality metrics and total-cost-of-care targets affects financial outcomes.

Beyond reimbursement, the industry is exposed to labor-cost inflation for nurses, technicians, and clinic staff; medical-supply chain risks for dialysis machines, dialyzers, and fluids; and pharmaceutical trends affecting anemia and bone-mineral management drugs used by dialysis patients. Commercial payor pricing is sensitive to broader employment-based insurance coverage. The international segment adds foreign-exchange, local regulatory, and geopolitical considerations across 14 countries, while any drug-pricing reform in the U.S. could ripple through the broader renal-care ecosystem even if DaVita is not a drug manufacturer.

Recent developments

Recent headlines have put DaVita back on traders’ radar. On August 26, 2026, Zacks reported that DaVita and Humana are expanding value-based care arrangements for kidney disease patients, directly aligned with the integrated-care priority noted in the 10-K. The same day, PR Newswire carried Alebund Pharmaceuticals’ 2026 interim results, a renal/pharma development worth watching because shifts in CKD drug treatment can affect downstream dialysis demand.

On August 27, 2026, a Fool.com headline noted that Warren Buffett and Greg Abel quietly hold a larger percentage of this company than any other in Berkshire Hathaway’s portfolio, hinting that notable ownership concentration could continue to influence sentiment and liquidity around the name. Then on August 28, 2026, Zacks highlighted outpatient and home healthcare stocks, including DaVita, as being in focus amid broader industry tailwinds.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten earnings estimates six times, for a 75% beat rate, with an average earnings surprise of 2.3%. The average five-day price move following those reports was 6.36% to the upside. Those averages, however, mask significant dispersion, and the current data make it clear that an EPS beat does not reliably translate into a positive post-earnings drift.

Looking at the four most recent quarters:

• 2026-08-04: Actual EPS of $4.02 versus an estimate of $3.88 produced a 3.6% beat, yet the stock fell 17.24% the next day and 21.78% over the following five days.
• 2026-05-05: Actual EPS of $2.87 versus an estimate of $2.41 produced a 19.1% beat; the stock rose 23.46% the next day and 27.7% over the next five days.
• 2026-02-02: Actual EPS of $3.40 versus an estimate of $3.24 produced a 4.9% beat; the stock gained 21.17% the next day and 23.79% over the next five days.
• 2025-10-29: Actual EPS of $2.51 versus an estimate of $3.17 was a -20.8% miss; the stock dropped 6.17% the next day and 4.27% over the next five days.

The August 2026 report is the standout cautionary example: a solid beat was overwhelmed by selling pressure, likely tied to forward guidance, reimbursement concerns, or broader sector rotation. The unofficial consensus for the next report, scheduled for October 28, 2026 after the close, currently stands at $3.58. Traders should note that with RSI at 31.6 and price well below the 50-day EMA, the next catalyst could produce another outsized move regardless of the headline beat or miss.

For readers who want to go further, the full institutional verdict, analyst consensus history, and detailed ownership breakdown on the DVA ticker page provide the deeper context needed to evaluate the stock beyond the numbers above.